Ambrosia’s AMB-702 Shows Superior Weight Loss in Preclinical GLP-1 Studies
BOULDER, Colorado, June 5, 2026 Ambrosia Biosciences has unveiled promising preclinical data for AMB-702, its novel oral small-molecule GLP-1...
ADA 2026
Advertisement
Lilly’s Foundayo Shows Strong Weight Loss Across Menopause
INDIANAPOLIS, Indiana, June 7, 2026 Eli Lilly and Company has announced new data demonstrating that Foundayo® (orforglipron), the only...
Zealand Pharma Reports Positive Phase 2 Petrelintide Data in Obesity
COPENHAGEN, Denmark, June 5, 2026 Zealand Pharma announced new results from its Phase 2 ZUPREME-1 clinical trial evaluating petrelintide,...
Rivus Highlights RV-8451 Muscle-Preserving Obesity Data
CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., June 5, 2026 Rivus Pharmaceuticals announced new preclinical data for RV-8451, its...
Structure Therapeutics Highlights Aleniglipron Phase 2b Success
SAN FRANCISCO, June 5, 2026 Structure Therapeutics Inc. announced the publication of detailed results from its Phase 2b ACCESS...
Advertisements
Ascletis Showcases Next-Generation Obesity Pipeline at ADA 2026
HONG KONG and NEW ORLEANS, Louisiana, June 8, 2026 Ascletis Pharma has strengthened its position in the highly competitive...
Berobenatide Shows Strong Weight Loss With Monthly Dosing
NEW ORLEANS, Louisiana, June 6, 2026 New data presented at the American Diabetes Association (ADA) 2026 Scientific Sessions have...
Novo Nordisk Reports Strong Phase 2 Zenagamtide Data
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 6, 2026 Novo Nordisk has announced positive results from a Phase 2 clinical...
Regeneron Highlights Phase 3 FOP and Metabolic Data
TARRYTOWN, N.Y., June 4, 2026 Regeneron Pharmaceuticals has unveiled a broad slate of new clinical and preclinical research across...
Cirius Therapeutics Highlights CIR-0602K as Promising New Therapy for Type 2 Diabetes
GRAND RAPIDS, Mich., June 1, 2026 Cirius Therapeutics has announced the presentation of new clinical data supporting CIR-0602K, its...
Advertisement
